Topic: Clostridium difficile (C. diff)
The financing positions MGB to generate clinical data in Clostridium difficile-associated diarrhea and prepare for the next steps in development.
Finch thinks it has a shot at winning FDA approval of the full-spectrum microbiota drug if the ongoing clinical study generates “compelling results.”
The antibiotic cadazolid was one of two experimental assets J&J acquired in its $30 billion takeover of Actelion last year.
Ferring sees the deal as an R&D acquisition that will keep delivering beyond the "front-runner project."
The funding will propel Finch's lead asset through phase 2 and advance its earlier-stage pipeline.
Locus Biosciences is moving ahead with a first clinical trial for its CRISPR-based antimicrobial drugs—armed with $19 million in series A funding.
PureTech affiliate Vedanta Biosciences announced a partnership to create immune-boosting cancer therapies that capitalize on the gut microbiome.
The combined company starts life with Crestovo’s phase 2 Clostridium difficile candidate and a large-scale stool donation program.
Actelion has posted mixed late-phase data on its antibiotic cadazolid.
Peter Thiel’s Breakout Labs continues apace as the nonprofit seed-stage fund has injected more cash into a host of biotechs, labs and startups.